Session Type: ACR Poster Session C
Session Time: 9:00AM-11:00AM
Background/Purpose: According different international registries, around one third of patients under biologic DMARD (bDMARD) with rheumatoid arthritis (RA) are receiving bDMARD as monotherapy (1-4). In Latin-American countries, the efficacy and survival of bDMARD as monotherapy is less well known (5). Our aim was to analyze efficacy and survival rates of bDMARD therapies (either anti TNF and non anti TNF) is a cohort of Colombian RA patients.
Methods: We conducted a cross-sectional study including patients with diagnosis of RA treated at Medicarte IPS from March 2009 to December 2016. Medicarte is a referral center for the integral medical care and pharmaco-surveillance of patients under biologic therapies in 13 cities in Colombia. Clinical information was obtained from electronic clinical records. Only those patients with complete information including disease activity indexes at baseline and at the last follow-up were included. We defined remission if DAS-28 (ESR) was < 2.6. Survival rates were analyzed using Kaplan-Meier survival curve. Patients were censored if fail to maintain remission or due to loss of follow-up
Results: From 1,020 patients with RA under bDMARD, we identified 139 (13.6%) patients treated as monotherapy. 90% of them were female with a mean age of 56.6 ± 10.9 years. Mean disease duration was 16.8 ± 9.9 years and mean time under bDMARD was 3.3 ± 2.4 years. Eighty three percent of patients were seropositive (FR and/or CCP) and mean DAS28 at baseline of bDMARD therapy was 4.23 ± 1.0. 102 (73%) out of 139 patients in monotherapy were on non anti TNF and 37 (27%) on anti TNF. From non-anti TNF therapies, tocilizumab was used in 52 patients, rituximab in 25 and abatacept in 25 patients. At last visit, remission rates were higher in patients under non-anti TNF vs anti TNF (70.6 vs 54%, p=0.069). Low disease activity rates were similar in both groups (77.5% vs 70.3%, p=0.384). Five year survival rates were significantly higher in patients treated with non-anti TNF vs anti TNF therapies. Among non-anti TNF therapies, survival rates were significantly higher in patients treated with tocilizumab, than in patients treated with rituximab or abatacept.
Conclusion: In our cohort of RA patients under bDMARD, 13% of patients are receiving biologic as monotherapy. Survival rates in terms of remission, were higher in patients under non anti TNF therapies, especially in patients treated with tocilizumab.
1. Heiberg MS, et al. Arthritis Rheum. 2008;59:234-240. 2. Soliman MM, et al. Ann Rheum Dis. 2011;70:583-589. 3. Listing J, et al. Arthritis Res Ther. 2006;8: R66. 4. Askling J, et al. Ann Rheum Dis. 2007;66:1339-1344. 5. Catay E et al . BMC Musculoskelet Disord. 2016;17:110.
To cite this abstract in AMA style:Gómez-Puerta JA, Duque Zapata N, Gonzalez LA, Cerón C, Vásquez M, Felipe Diaz OJ. Efficacy and Survival of Biologic DMARD Therapies As Monotherapy: Real World Data [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/efficacy-and-survival-of-biologic-dmard-therapies-as-monotherapy-real-world-data/. Accessed January 22, 2020.
« Back to 2017 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/efficacy-and-survival-of-biologic-dmard-therapies-as-monotherapy-real-world-data/